Literature DB >> 26542176

Endostatin exerts radiosensitizing effect in non-small cell lung cancer cells by inhibiting VEGFR2 expression.

L Liu1, Y Qiao2, C Hu2, Y Liu1, Y Xia2, L Wang2, B Liu1, H Chen1, X Jiang3.   

Abstract

BACKGROUND: To determine the effects of endostatin on vascular growth factor receptor 2 (VEGFR2) expression in non-small cell lung cancer (NSCLC) cells and the mechanisms underlying its radiosensitizing effect.
METHODS: VEGFR2 mRNA levels were determined in different NSCLC cell lines using qRT-PCR. RT-PCR and Western blot assays were used to assess the expression of mRNA and proteins. The radiosensitivity of the cells was determined by colony-formation assays; and cell apoptosis and cell cycle distribution were determined by flow cytometry.
RESULTS: VEGFR2 mRNA levels differed among the five NSCLC cell lines (P < 0.01), with the highest expression in Calu-1 cells and lowest in A549 cells. Endostatin significantly inhibited the growth of Calu-1 cells (P < 0.01) (IC20 = 296.5 μg/ml), and the expression of VEGFR2 and HIF-1α (P < 0.05). Phosphorylation of protein kinase B (Akt), extracellular signal-regulated kinases 1/2 (ERK1/2), and p38 were significantly lower in endostatin-treated cells than control (P < 0.05). Endostatin enhanced the radiosensitivity of Calu-1 cells to SER = 1.38 and induced apoptosis (P < 0.01) and G2/M blockage (P < 0.01). However, endostatin had limited effects on A549 cells. Compared with Calu-1 cells, there was not significantly effects on cell radiosensitivity (SER = 1.09).
CONCLUSIONS: Endostatin induces apoptosis and enhances radiosensitivity of the VEGFR2 high-expressing cell line Calu-1, but it has a limited effect on the VEGFR2 low-expressing cell line A549.

Entities:  

Keywords:  Endostatin; HIF-1α; NSCLC; Radiosensitivity; VEGFR2

Mesh:

Substances:

Year:  2015        PMID: 26542176     DOI: 10.1007/s12094-015-1319-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  19 in total

1.  Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.

Authors:  Fei Yang; Ximing Tang; Erick Riquelme; Carmen Behrens; Monique B Nilsson; Uma Giri; Marileila Varella-Garcia; Lauren A Byers; Heather Y Lin; Jing Wang; Maria G Raso; Luc Girard; Kevin Coombes; J Jack Lee; Roy S Herbst; John D Minna; John V Heymach; Ignacio I Wistuba
Journal:  Cancer Res       Date:  2011-07-01       Impact factor: 12.701

Review 2.  Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer.

Authors:  Faton Agani; Bing-Hua Jiang
Journal:  Curr Cancer Drug Targets       Date:  2013-03       Impact factor: 3.428

3.  Biochemical and molecular analysis of the interaction between ERK2 MAP kinase and hypoxia inducible factor-1α.

Authors:  Athanasios Karapetsas; Antonis Giannakakis; Maria Pavlaki; Mihalis Panayiotidis; Raphael Sandaltzopoulos; Alex Galanis
Journal:  Int J Biochem Cell Biol       Date:  2011-07-22       Impact factor: 5.085

4.  MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300.

Authors:  Nianli Sang; Daniel P Stiehl; Jolene Bohensky; Irene Leshchinsky; Vickram Srinivas; Jaime Caro
Journal:  J Biol Chem       Date:  2003-02-13       Impact factor: 5.157

Review 5.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

Authors:  J M Brown; A J Giaccia
Journal:  Cancer Res       Date:  1998-04-01       Impact factor: 12.701

6.  Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1.

Authors:  Young-Mi Kim; Sewook Hwang; Young-Myoeng Kim; Bo-Jeong Pyun; Tae-Yoon Kim; Seung-Taek Lee; Yong Song Gho; Young-Guen Kwon
Journal:  J Biol Chem       Date:  2002-05-23       Impact factor: 5.157

Review 7.  Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications.

Authors:  Alexander Chi; Zhongxing Liao; Nam P Nguyen; Jiahong Xu; Baldassarre Stea; Ritsuko Komaki
Journal:  Radiother Oncol       Date:  2010-01-13       Impact factor: 6.280

8.  Study on lung cancer cells expressing VEGFR2 and the impact on the effect of RHES combined with radiotherapy in the treatment of brain metastases.

Authors:  Xiao-dong Jiang; Man-hua Ding; Yun Qiao; Yi Liu; Liang Liu
Journal:  Clin Lung Cancer       Date:  2013-11-20       Impact factor: 4.785

9.  Efficient approach for determining four-dimensional computed tomography-based internal target volume in stereotactic radiotherapy of lung cancer.

Authors:  Seung-Gu Yeo; Eun Seog Kim
Journal:  Radiat Oncol J       Date:  2013-12-31

10.  MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines.

Authors:  S Grosso; J Doyen; S K Parks; T Bertero; A Paye; B Cardinaud; P Gounon; S Lacas-Gervais; A Noël; J Pouysségur; P Barbry; N M Mazure; B Mari
Journal:  Cell Death Dis       Date:  2013-03-14       Impact factor: 8.469

View more
  6 in total

1.  Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report.

Authors:  Liang Liu; Xin Zhang; Lihua Zhou; Tao Yang; Yun Qiao; Xiaodong Jiang
Journal:  Medicine (Baltimore)       Date:  2021-09-03       Impact factor: 1.817

Review 2.  Angiogenesis, Lymphangiogenesis, and Inflammation in Chronic Obstructive Pulmonary Disease (COPD): Few Certainties and Many Outstanding Questions.

Authors:  Remo Poto; Stefania Loffredo; Francesco Palestra; Gianni Marone; Vincenzo Patella; Gilda Varricchi
Journal:  Cells       Date:  2022-05-23       Impact factor: 7.666

3.  Role of the NRP-1-mediated VEGFR2-independent pathway on radiation sensitivity of non-small cell lung cancer cells.

Authors:  Chenxi Hu; Panrong Zhu; Youyou Xia; Kaiyuan Hui; Mei Wang; Xiaodong Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-17       Impact factor: 4.553

4.  Effects of combined inhibition of STAT3 and VEGFR2 pathways on the radiosensitivity of non-small-cell lung cancer cells.

Authors:  Chenxi Hu; Wei Zhuang; Yun Qiao; Bin Liu; Liang Liu; Kaiyuan Hui; Xiaodong Jiang
Journal:  Onco Targets Ther       Date:  2019-01-29       Impact factor: 4.345

5.  A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways.

Authors:  Lin Li; Yuexian Li; Huawei Zou
Journal:  PeerJ       Date:  2021-10-28       Impact factor: 2.984

6.  HYD-PEP06 suppresses hepatocellular carcinoma metastasis, epithelial-mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K/AKT and WNT/β-catenin signaling activation.

Authors:  Wei Tian; Jiatong Li; Zhuo Wang; Tong Zhang; Ying Han; Yanyan Liu; Wenfeng Chu; Yu Liu; Baofeng Yang
Journal:  Acta Pharm Sin B       Date:  2021-04-02       Impact factor: 11.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.